[12] Patent
[11] Patent No.:GC0004539  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/89718
Date of the Decision to Grant the Patent:18/Dec/2016

[21] Application No.:GC 2011-20090

[22] Filing Date:21/12/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
14/1/2011
61/432.958

[72] Inventors:1- David Anthony Barda،2- Mary Margaret Mader

[73] Owner: Eli Lilly and company, Lilly Corporate Center, City of Indianapolis, 46285, Indiana, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4745; A61P 35/00; C07D 471/04 (2006.01)

[56] Cited Documents:

-WO 2010139747 Al (NOVARTIS AG [CH]; FURET PASCAL [CH]; IMBACH PATRICIA [CH]; MAH ROBERT) 9 December 2010
-WO 2010038165 A1 (PFIZER [US]; CHENG HENGMIAO [US]; JOHNSON TED WILLIAM [US]; HOFFMAN JA) 8 April 2010
 
Examiner: PH. Nada A. AlShamrani

[54] PI3 KINASE/mTOR DUAL INHIBITOR
[57] Abstract: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.
No. of claims: 10


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.